TABLE 4

Demographic and Clinical Factors Associated With Severe LRTI Versus Nonsevere LRTI Hospitalizations in Commercial and Medicaid Databases, 2007–2011

Demographic and Clinic CharacteristicsCommercial (N = 120 516)Medicaid (N = 96 006)
Nonsevere LRTISevere LRTIRelative Risk (95% CI)Nonsevere LRTISevere LRTIRelative Risk (95% CI)
(N = 104 453)% of Total(N = 16 063)% of Total(N = 81 953)% of Total(N = 12 053)% of Total
Age group, y
 <134 92133.4644940.10.91 (0.87–0.96)45 55055.6700858.10.63 (0.59–0.67)
 117 66616.9194512.10.54 (0.51–0.58)10 94213.411429.50.42 (0.39–0.47)
 2–422 48421.5272216.90.60 (0.56–0.64)13 05015.9155812.90.49 (0.45–0.53)
 5–916 69616.0238914.90.70 (0.67–0.75)73939.011179.30.62 (0.57–0.68)
 10–1812 68612.1255815.9Reference50186.1122810.2Reference
Gender
 Boy59 27556.7910156.71.00 (0.97–1.04)46 24256.4672155.81.02 (0.98–1.07)
 Girl45 17843.3696243.3Reference35 70043.6532644.2Reference
Racea
 WhiteNANANA39 48248.2505742.0Reference
 African AmericanNANANA21 99626.8325427.01.2 (1.1–1.3)
 HispanicNANANA65918.010919.11.3 (1.2–1.4)
 OtherNANANA13 78216.8261721.71.5 (1.4–1.6)
Outcomeb
 Survived104 42710015 90999.0Reference81 93599.9811 89598.7Reference
 Died260.021541.038.8 (25.6–58.9)180.021581.360.4 (37.1–98.5)
Previous LRTI hospital
 0100 40796.115 16494.4Reference76 14792.910 86090.1Reference
 ≥140463.98995.61.5 (1.4–1.6)58067.111939.91.4 (1.3–1.5)
At least 1 underlying medical conditionc
 056 65054.2393024.5Reference37 46445.7194216.1Reference
 ≥147 80345.812 13375.53.6 (3.5–3.7)44 48954.310 11183.94.4 (4.2–4.6)
Number of underlying medical conditions
 056 65054.2393024.5Reference37 46445.7194216.1Reference
 131 42530.1605237.72.7 (2.6–2.9)23 28428.4353929.42.9 (2.7–3.1)
 210 0639.6331520.64.7 (4.5–5.0)988412.1219218.24.3 (4.0–4.6)
 ≥363156.0276617.26.3 (6.0–6.7)11 32113.8438036.37.5 (7.1–7.9)
Specific conditiond
 Asthma19 74418.9318219.81.1 (1.0–1.2)12 67415.5197816.41.1 (1.0–1.13)
 Other pulmonary diseases22 69821.7898355.94.6 (4.4–4.7)23 58328.8820368.15.3 (5.1–5.5)
 Cardiac disease64106.1283017.63.3 (3.1–3.4)75159.2309325.73.4 (3.2–3.5)
 Renal disease5660.52241.42.6 (2.2–3.0)4900.61931.62.7 (2.3–3.2)
 Hemoglobinopathies15611.54132.61.7 (1.5–1.9)22462.73923.31.2 (1.1–1.3)
 HIV/AIDS260.0120.13.0 (1.5–5.9)850.1120.11.0 (0.5–1.7)
 Immunosuppression18841.85103.21.8 (1.6–2.0)22922.88397.02.6 (2.4–2.8)
 Malignancy13551.34212.62.0 (1.8–2.3)8381.02572.12.1 (1.8–2.4)
 Diabetes8930.92751.72.3 (2.0–2.6)9131.13012.52.3 (2.0–2.6)
 Other metabolic disorder10811.03492.22.1 (1.9–2.4)32343.96045.01.3 (1.1–1.4)
 Obesity5010.51330.81.7 (1.4–2.1)7470.91691.41.5 (1.3–1.8)
 Liver disease2400.2880.52.4 (1.9–3.1)2140.3840.72.7 (2.1–3.1)
 Neurologic disorder69546.7253815.82.6 (2.5–2.7)71548.7261921.72.9 (2.8–3.5)
 Cerebrovascular disease6120.62871.83.1 (2.7–3.6)8731.13953.33.1 (2.8–3.5)
 Pregnancy complications18301.84382.71.6 (1.4–1.7)13 91317.0381231.62.3 (2.2–2.4)
 Prematurity61235.94382.72.2 (2.1–2.3)80689.8251720.92.4 (2.3–2.5)
 Other congenital disorder22832.29165.72.7 (2.5–2.9)14211.75824.82.9 (2.7–3.2)
  • CI, confidence interval; NA, not applicable.

  • a Race is not available for enrollees in the commercial database.

  • b Outcome is determined at time of discharge.

  • c Relative risk is determined by comparing those with the medical condition to those without the medical condition.

  • d The specific conditions are listed in Supplemental Table 9.